Healthy Pulp, Irreversible Pulpitis, Reversible Pulpitis
Conditions
Keywords
Pulpitis, Irreversible Pulpitis, Pulp Blood, Biomarkers, Dental Pulp, ELISA
Brief summary
This observational study aims to evaluate the role of inflammatory, oxidative stress, neurogenic, and immunological biomarkers obtained from pulpal blood in the differential diagnosis of normal pulp, reversible pulpitis, and irreversible pulpitis. A total of 75 teeth from systemically healthy individuals aged 12-35 years will be included and classified into three groups: normal pulp, reversible pulpitis, and irreversible pulpitis, based on clinical examination, radiographic findings, and pulp sensibility tests. No additional treatment procedures will be performed for research purposes. All dental procedures will be carried out according to routine clinical protocols. During routine treatment, after pulp exposure, approximately 50 μL of pulpal blood that would otherwise be discarded as medical waste will be collected using a micropipette. Samples will be stored and analyzed using Enzyme-Linked ImmunoSorbent Assay (ELISA) to determine the levels of inflammatory, neurogenic, immunological, and oxidative stress biomarkers. The results will be compared among the three groups to identify biomarkers that may improve the accuracy of pulpitis diagnosis and support clinical decision-making.
Detailed description
Current diagnosis of pulpal status relies primarily on clinical symptoms, sensibility tests, and radiographic findings, which may not always accurately reflect the underlying histopathological condition of the pulp. This study aims to investigate inflammatory, neurogenic, immunological, and oxidative stress biomarkers obtained from pulpal blood samples collected during routine dental treatment. Biomarker levels will be compared among teeth with normal pulp, reversible pulpitis, and irreversible pulpitis. The findings may contribute to the development of objective diagnostic tools for more accurate differentiation of pulpal conditions and improved treatment decision-making.
Interventions
DIAGNOSTIC_TESTPulpal Blood Biomarker Analysis
Collection of pulpal blood samples during routine dental treatment followed by biomarker analysis using ELISA.
Sponsors
Safa
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
12 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Individuals aged 12 to 35 years * Systemically healthy individuals * Patients presenting for routine restorative treatment or root canal treatment * Teeth classified into one of the following pulpal status groups: healthy pulp, reversible pulpitis, or irreversible pulpitis * Confirmation of pulp vitality by pulp sensibility tests * Ability to obtain pulp exposure and collect an adequate pulpal blood sample during treatment
Exclusion criteria
* No response to pulp sensibility tests * Teeth that are not restorable * Presence of a sinus tract * Radiographic evidence of periapical pathology * Presence of internal or external root resorption * Teeth with open apices * Presence of systemic disease * Pregnancy * History of non-steroidal anti-inflammatory drug (NSAID) or antibiotic use within the last week * Requirement for prophylactic antibiotic use * Teeth in which pulp exposure cannot be achieved after complete caries removal
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Levels of inflammatory, neurogenic, immunological, and oxidative stress biomarkers in pulpal blood samples | At the time of treatment (baseline) | Comparison of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-10 (IL-10), matrix metalloproteinase-9 (MMP-9), transforming growth factor-beta 1 (TGF-β1), presepsin, substance p, semaphoric 3A (SEMA3A), semaphoric 4D (SEMA4D), semaphoric 7A (SEMA7A), total antioxidant status (TAS), total oxidant status (TOS), malondialdehyde (MDA), glutathione (GSH), and superoxide dismutase (SOD) levels among healthy pulp, reversible pulpitis, and irreversible pulpitis groups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic performance of pulpal blood biomarkers | At the time of treatment (baseline) | Evaluation of the ability of measured biomarkers to differentiate healthy pulp, reversible pulpitis, and irreversible pulpitis. |
Countries
Turkey (Türkiye)
Outcome results
None listed